74 results about "Activating macrophage" patented technology

The invention provides an in-vitro skin blood vessel immune model as well as a preparation method and application thereof. THP-1 human monocyte leukemia cells are induced to be differentiated into M0 type macrophages, and then the M0 type macrophages are respectively induced into M1 type macrophages and / or M2 type macrophages; then co-culturing the M1 type and / or M2 type macrophages and vascular endothelial cells to form a vascular immune model; finally, the 3D skin model is placed on the blood vessel immune model, external stimulation is conducted, and the in-vitro skin blood vessel immune model is constructed. The in-vitro skin blood vessel immune model can be used for repairing skin barriers, inflammation pathways, blood vessel metabolism, the expression level of genes or proteins related to extracellular matrixes, vascular endothelial cells, the proliferation and migration ability of activated macrophages and the like. The seven feature dimensions of the physiological structure feature of the skin model are used for screening the to-be-tested sample and exploring the action mechanism, and the method has the characteristics of rapidness, multiple screening dimensions, high accuracy, low construction difficulty, low cost and high universality.

The invention relates to the technical field of microorganisms, in particular to bifidobacterium bifidum BGLP1 capable of regulating sugar digestion and producing GLP-1 at high yield and application of the bifidobacterium bifidum BGLP1. The preservation number of the bifidobacterium bifidum BGLP1 is CGMCC (China General Microbiological Culture Collection Center) No.35718, and the bifidobacterium bifidum BGLP1 can be used for preparing the feed additive. The strain has the capability of inhibiting alpha-glucosidase and alpha-amylase; sTC-1 cells are stimulated to secrete GLP-1, and the blood glucose reducing pathway capacity of the intestinal tract is activated; the activity of pancreatic lipase is obviously inhibited, and the dietary fat absorption capability can be effectively reduced; redundant cane sugar is converted into exopolysaccharide, so that the probiotic function capability is improved; the capability of converting white fat into brown fat is promoted; macrophages are activated, and the body immune function is improved. In addition, the bifidobacterium bifidum BGLP1 also has relatively strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can smoothly reach the intestinal tract of a human body.

The invention relates to the technical field of microorganisms, and particularly discloses lactobacillus plantarum WCSF1-0012 and application thereof.The lactobacillus plantarum WCSF1-0012 is preserved in the China General Microbiological Culture Collection Center on December 19, 2024, the preservation number is CGMCC No.33131, and the lactobacillus plantarum WCSF1-0012 is preserved in the China General Microbiological Culture Collection Center on December 19, 2024. The special gene sequence of the lactobacillus plantarum WCSF1-0012 is as shown in SEQ ID NO. 1; the lactobacillus plantarum WCSF1-0012 is used for preparing medicines, health-care products or food drinks for preventing, inhibiting or treating oral tumors. The lactobacillus plantarum WCSF1-0012 is a safe probiotic free of toxic and side effects, can effectively inhibit oral tumors, can play an anti-tumor role by activating macrophages, has long-term practical safety, is low in cost, high in safety and high in reliability, and can be used for preparing medicines or food drinks for preventing and even treating oral tumors.

The present invention relates to alternatively activated macrophages (AAMs) for use in the treatment of liver injury and methods of treating and preventing liver injury using AAMs.

This invention belongs to the field of plant extract technology, specifically relating to a plant extract composition for enhancing immunity. By weight, it is composed of the following raw materials: 3-5 parts Astragalus membranaceus extract, 2.5-4 parts Echinacea purpurea extract, and 1.5-3.5 parts Rhodiola rosea extract. This plant extract composition, through the scientific formulation of Astragalus membranaceus, Echinacea purpurea, and Rhodiola rosea, and an enzymatic extraction process, enhances the immunomodulatory effect. The combination of the three extracts increases the secretion of TNF-α and IL-6 by macrophages. Furthermore, the spleen lymphocyte stimulation index (SI) of the three extracts reaches 5.57, and the lymphocyte transformation rate increases from 191% to 457%. These results indicate that this plant extract composition effectively enhances the body's non-specific and cellular immune functions by activating macrophages and promoting T lymphocyte proliferation through multiple pathways, providing more comprehensive immune protection.

The application discloses a kind of nanoclusters with golgi targeting and its preparation method and application, the nanocluster is zinc sulfide nanocluster, the surface of the zinc sulfide nanocluster is coupled with targeting ligand, the targeting ligand can actively target RA synovial activated macrophage, and can target golgi subcellular organelle, the nanocluster can release H2S gas in inflammatory weak acid microenvironment.The application can realize "inflammatory joint enrichment-> macrophage active uptake-> lysosome escape-> golgi deep anchoring" multi-level precise delivery, release H2S gas in inflammatory weak acid microenvironment, fundamentally reshape intracellular Ca 2+ Steady state, relieve endoplasmic reticulum, golgi and mitochondria triple stress, block inflammatory signal pathway, realize the efficient, safe treatment of RA.

The invention discloses araban obtained from fructus lycii and application of the araban. According to the molecular structure of the araban, a main chain is formed by repeated-> 5)-alpha-Araf-(1-> structural units, and the C-2 position of each sugar residue is substituted by T-alpha-Araf-(1-> structural units. According to the method, free protein is removed through a water extraction and alcohol precipitation method and an alkali solution method, graded alcohol precipitation and purification are combined, and the araban component only containing arabinose is extracted and separated from the fructus lycii for the first time. Compared with an arabinogalactan component, the arabinogalactan component has the advantages that the phagocytic ability of macrophages is remarkably improved, the macrophages are induced to secrete NO, the activity of acid phosphatase is improved, the phagocytic ability of the macrophages and the activity of the acid phosphatase can be activated in an LPS-induced inflammation model, NO secretion is inhibited, and the arabinogalactan component can be used for preparing an LPS-induced inflammation model. Therefore, an anti-inflammatory effect is generated, and a better bidirectional immunoregulation effect is achieved.

The present application relates to the technical field of microorganisms, and particularly relates to a bifidobacterium BGLP1 capable of regulating sugar digestion and high GLP-1 production and application thereof. Bifidobacterium bifidum The bifidobacterium BGLP1 (CGMCC No. 35718) has the abilities of inhibiting alpha-glucosidase and alpha-amylase, stimulating STC-1 cells to secrete GLP-1 and activating the intestinal glucose-lowering pathway, significantly inhibiting pancreatic lipase activity and effectively reducing dietary fat absorption, converting excess sucrose into extracellular polysaccharides to increase the probiotic function, promoting the conversion of white fat into brown fat, and activating macrophages and improving the immune function of the body. In addition, the bifidobacterium BGLP1 has strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can successfully reach the human intestinal tract.

The invention discloses an application of an RGS1 gene inhibitor in preparation of a medicine for treating obesity-related metabolic diseases, relates to the technical field of biological medicines, and particularly relates to an application of the RGS1 gene inhibitor in preparation of a medicine for treating obesity-related metabolic diseases. The inhibitor of the RGS1 gene is used for preparing a medicine for treating obesity-related metabolic inflammatory diseases, and the medicine is used for activating a PINK1 / Parkin mediated mitochondrial autophagy pathway in macrophages; the inhibitor of the RGS1 gene is a shRNA (short hairpin Ribonucleic Acid) lentiviral expression vector capable of realizing targeted silencing of RGS1 gene expression; the application of the RGS1 gene inhibitor in preparation of drugs for treating obesity-related metabolic diseases has significant beneficial effects; the drug can accurately activate a PINK1 / Parkin mediated mitochondrial autophagy pathway in macrophages, has high targeting property, and improves the safety and effectiveness of the drug.

The present application relates to the field of microbial technology, and particularly relates to bifidobacterium BB36 with improved antigen presentation ability and enriched calcium, iron and selenium, probiotics and application thereof. Bifidobacterium bifidum The present application provides bifidobacterium BB36 with activated macrophages, up-regulated immune factor expression level, and activated dendritic cells, enhanced antigen presentation ability in immune process, and enriched calcium, iron and selenium, and can be used as a biological carrier of mineral elements, in addition, can inhibit the growth of escherichia coli and staphylococcus aureus, and protect intestinal health of the body.

The invention provides an engineered immune cell and application thereof, and relates to the technical field of biology. The cell membrane of the engineered immune cell expresses the chimeric antigen receptor; the antibody or the antigen binding fragment of the antibody specifically binding to CD47 is expressed by the overexpression cytokine of the antibody or the antigen binding fragment of the antibody. The engineered immune cell can efficiently activate macrophages, and the tumor treatment effect is improved.

This invention relates to the field of pharmaceutical technology, specifically to the novel use of avenanthramide A in the preparation of drugs for repairing liver damage. Experiments have demonstrated that the addition of avenanthramide A to activated macrophages significantly promotes the expression of tumor necrosis factor-α (TNF-α). Furthermore, co-culturing macrophages stimulated with avenanthramide A with hepatocytes effectively promotes hepatocyte proliferation. The addition of a TNF-α neutralizing antibody reverses this proliferative effect. This experiment confirms that avenanthramide A can promote hepatocyte proliferation and liver damage repair by increasing TNF-α expression in macrophages. This invention provides a novel drug target for enhancing hepatocyte proliferation.

The present invention relates to the technical field of tea products, and discloses an immunity enhancing instant Pu'er tea powder, which comprises, by mass, 55%-70% of a Pu'er tea extract, 1.5%-3.0% of beta-glucan, 0.5%-1.2% of lactoferrin, 3-0.05%-0.15% of vitamin D, 3.0%-5.0% of a tea polyphenol concentrate, and the balance of a microencapsulation carrier. According to the instant Pu'er tea powder capable of enhancing immunity and the preparation method of the instant Pu'er tea powder, beta-glucan, lactoferrin, vitamin D3 and a tea polyphenol concentrate are precisely proportioned, the beta-glucan activates macrophages to phagocytize pathogens, the lactoferrin inhibits inflammatory response, the vitamin D3 promotes immune cell maturation, and the tea polyphenol concentrate is added into the instant Pu'er tea powder. Catechin and caffeine in the tea polyphenol concentrate synergistically resist oxidation, through mixed extraction of cooked tea and raw tea and step-by-step enzymolysis of cellulase and beta-glucanase, the extraction rate of theabrownin and beta-glucan is remarkably increased, and a material basis is provided for immunoregulation.

The present invention relates to a composition for preventing, improving and treating an inflammatory macrophage-mediated autoimmune disease, including a stem cell-derived exosome surface-modified with a sugar compound to target an activated macrophage, and the composition according to the present invention may specifically target an activated macrophage to increase the therapeutic efficiency for various types of autoimmune diseases including rheumatoid arthritis. In addition, the composition according to the present invention has a more excellent therapeutic effect and minimizes side effects compared with conventional antiinflammatory agents, stem cell therapeutic agents or exosomes because it contains a gene, protein or growth factor related to the proliferation, differentiation and regeneration of stem cells, and does not include an antibiotic or serum, or harmful factors of the cell culture.

The present invention relates to the use of LRG1 in the preparation of a drug for promoting macrophage differentiation into the M1 type and a macrophage activator. The present invention discovers that LRG1 activates macrophages and induces their differentiation into the pro-inflammatory M1 type, thus representing a new inducing factor for macrophage activation. This invention provides a novel mechanism for macrophage activation and offers new targets and approaches for the prevention and treatment of inflammatory responses, inflammatory-related diseases, and tumors.

The invention discloses application of triptolide ketone in preparation of a medicine for treating sepsis lung injury, and belongs to the technical field of biological medicine. Aiming at the problems that traditional chemical synthetic drugs may cause a large amount of sequelae and antibiotic abuse, and triptolide may cause liver and kidney injury when treating sepsis, research finds that triptolide can be used for treating sepsis lung injury, and can be used for treating sepsis lung injury. According to the application, the protein expression level of HIF-1alpha in proinflammatory activated macrophages is lowered, so that aerobic glycolysis is inhibited, and the effect of treating sepsis lung injury is achieved. Compared with the triptolide alcohol, the triptolide ketone does not cause liver and kidney injury while playing a role in treating the sepsis lung injury, and the curative effect of the triptolide ketone is equivalent to that of the existing medicine 2ME2 for treating the sepsis lung injury, so that the triptolide ketone has important application potential clinically, and can be used for preparing medicines for treating the sepsis lung injury. And a theoretical basis is provided for clinically developing medicines for treating sepsis lung injury.

The invention belongs to the technical field of medicine, and particularly relates to novel application of oat alkaloid A in preparation of medicine for repairing liver injury. Experiments prove that the expression of a tumor necrosis factor TNF-alpha can be remarkably promoted by adding the avenanthramide A into the activated macrophages, the proliferation of the hepatocytes can be effectively promoted after the macrophages stimulated by the avenanthramide A and the hepatocytes establish a co-culture system, and the proliferation effect of the hepatocytes is reversed after a TNF-alpha neutralizing antibody is added. The experiment proves that the oat alkaloid A can promote liver cell proliferation and liver injury repair by improving TNFa expression of macrophages. The invention can provide a new drug target for improving hepatocyte proliferation.

The invention discloses a radix fici simplicissimae polysaccharide extract and a preparation method and application thereof.The radix fici simplicissimae polysaccharide extract is radix fici simplicissimae crude polysaccharide or purified polysaccharide, and the radix fici simplicissimae crude polysaccharide is obtained by conducting primary alcohol precipitation, Sevage method protein removal and secondary alcohol precipitation on a radix fici simplicissimae water extract and then conducting drying; the purified polysaccharide is obtained by performing DEAE-52 fiber column chromatography on RFH, eluting by taking a sodium chloride solution as an eluent, respectively collecting elution parts of 0.3 mol / L sodium chloride solution, 0.4 mol / L sodium chloride solution and 0.5 mol / L sodium chloride solution, and respectively performing dialysis and drying. The radix fici simplicissimae polysaccharide extract prepared through a limited method can effectively activate macrophages to generate immunocompetence and is expected to be used for preparing immunomodulators or related drugs or food for enhancing the immunologic function.

The invention provides a plant polysaccharide with an immunomodulatory function, an extraction method thereof and an immunomodulator, and relates to the technical field of plant polysaccharides. The extraction method provided by the invention comprises the following steps: carrying out alcohol extraction on plant raw materials, and then separating alcohol extraction residues; carrying out water extraction on the alcohol extraction residues, and separating to obtain a water extract; carrying out concentration and alcohol precipitation on the water extract, and centrifuging to obtain a polysaccharide mixture; deproteinizing, dialyzing and freeze-drying the polysaccharide mixture to obtain plant polysaccharide; the plant raw material is one of clover leaves, fairy leaves and banana flowers. According to the extraction method provided by the invention, the plant polysaccharide with relatively high immunocompetence can be obtained, and the plant polysaccharide effectively activates immune effector cells such as macrophages and promotes secretion of cytokines through a bidirectional immunoregulation effect, so that safe raw materials can be provided for developing products for enhancing body defense and maintaining immune balance.

The application discloses a kind of nucleic acid nano vesicles based on sulfonium copolymerization peptide and its preparation method and application.The vesicle is formed by the electrostatic self-assembly of a kind of sulfonium copolymerization peptide and polynucleotide, and is stable nano vesicle with hollow structure.The vesicle is different from conventional solid nanoparticles, and its unique hollow structure provides space for co-loading other therapeutic agents (such as enzymes, chemotherapeutic drugs).The application also provides a preparation method of the nano vesicle, and its application as a carrier for simultaneously loading nucleic acid drugs and other active ingredients for synergistic treatment.The nano vesicle has extraordinary long-term storage stability, and can deliver siRNA and catalase to tumor sites, block CD47 "don't eat me" signal through gene silencing, and enzymatically degrade immunosuppressive factor H2O2 in tumor microenvironment, thereby remodeling tumor immune microenvironment, efficiently activating macrophages, dendritic cells and T cells, and producing strong synergistic anti-tumor immune effect.

The application belongs to the field of tea polysaccharide research, and discloses a Zijuan tea polysaccharide ZTPW with immunoregulatory activity, and a preparation method and application thereof. The ZTPW is a uniform polysaccharide obtained by hot water extraction and alcohol precipitation of Zijuan tea leaves, and separation and purification through an ion exchange column and a gel column, the main repeating unit structure of which is shown in the following, and the weight average molecular weight thereof is 7.73 kDa. Through in vitro immunoregulatory activity research, the ZTPW can be recognized by pattern recognition receptors TLR2 and TLR4 to activate macrophages, significantly enhance the activity of mouse monocyte macrophage RAW264.7 cells, and mediate the production of NO and cytokines of mouse monocyte macrophage RAW264.7 through MAPKs and NF-kappa B signal pathway, so as to play an immunoregulatory role. The polysaccharide can be used as a potential immunoregulator for the development of functional food or medicine.

The invention relates to a fusion polypeptide for diabetes wound repair and a pharmaceutical composition thereof, and discloses a sequence design and a preparation method of the fusion polypeptide FP-DW01-Chol, and a temperature-sensitive hydrogel composition containing the polypeptide and MitoQ. The fusion polypeptide contains a TREM2 agonist domain, an AGE-RAGE blocking domain, an MMP9 recognition cleavage site, an Angiopoietin-2 mimic peptide fragment and a cholesterol modification terminal, and can activate anti-inflammatory polarization of macrophages, block a chronic inflammation pathway and respond to a wound enzyme environment to release an angiogenesis promoting fragment. The pharmaceutical composition takes poloxamer 407 / 188 as a temperature-sensitive carrier, realizes cooperative delivery of polypeptide and MitoQ, and has the advantages of slow release, skin retention and stability. In-vitro and db / db mouse model experiments prove that the composition can remarkably promote high-glucose damaged cell activity recovery, inhibit inflammatory factor release, accelerate wound closure, promote angiogenesis and tissue remodeling, provides a multi-mechanism synergistic and local long-acting treatment scheme for diabetic refractory wounds, and has important clinical transformation value.

The present application relates to the technical field of biological medicine, in particular to a new application of a BTK PROTAC compound NX-5948, especially to a new application of a Bruton's tyrosine kinase protein degradation targeting chimera BTK PROTAC compound NX-5948 in a drug for treating secondary hemophagocytic syndrome (HLH). In the present application, the BTK PROTAC compound NX-5948 inhibits the activation of the macrophage BTK / NF-κB axis signaling pathway through targeting, on the one hand, reduces the number of activated macrophages by inhibiting the proliferation and survival of macrophages, on the other hand, induces the polarization of macrophages from pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages through the immunoregulatory effect on macrophages, and then inhibits the release of cytokines and the occurrence and development of HLH, so that the effect of the new application of the present application is that it can inhibit the abnormal activation of macrophages and improve the clinical symptoms or laboratory indexes existing in patients with secondary hemophagocytic syndrome.

The present invention discloses the application of MTHFD2 in reprogramming macrophage polarization by inhibiting PTEN. The present invention discovered for the first time that MTHFD2 inhibits the polarization of IFN-γ-activated macrophages in vitro and in vivo, but enhances the polarization of IL-4-activated macrophages, and determined that MTHFD2 is a regulator of macrophage polarization. Further experiments found that MTHFD2 leads to macrophage polarization reprogramming by inhibiting the PIP3 phosphatase activity of PTEN and enhancing the activation of downstream Akt. In addition, the present invention also found that myeloid deletion of MTHFD2 slowed tumor progression, promoted liver fibrosis, and reduced the recruitment of eosinophils. The present invention not only clarifies the previously unknown non-metabolic function of MTHFD2 in regulating PTEN activity, but also proposes a possible strategy for targeting MTHFD2 to regulate macrophage-mediated immune responses.

The present invention relates to the field of dressings and specifically discloses a method for preparing a recombinant dual-protein medical dressing. The dressing provided herein has low irritation. By compounding recombinant mussel mucin and recombinant humanized type III collagen, the dressing isolates viral hazards and rejection reactions, achieving rapid repair of traumatic skin. Furthermore, by treating β-glucan, the dressing enhances its ability to activate macrophages, promoting the secretion of growth factors and collagen. When used in combination with recombinant humanized type III collagen, the dressing accelerates fibroblast proliferation.

The present disclosure provides methods and compositions related to the combination therapy of a macrophage-directed immunotherapy and a cytokine (e.g., IL-10). The combination of the macrophage-directed immunotherapy and a cytokine is useful in treating and / or preventing cancer (e.g., lung cancer) in a subject. Therapies that activate macrophages are emerging in cancer immunotherapy. One potential therapeutic target is the CD47-SIRPa, interaction, which acts as a myeloid immune checkpoint. Cluster of Differentiation 47 (CD47) is highly expressed on many different types of cancer cells, including lung cancer cells. CD47 binds to an inhibitory receptor, signal regulatory protein alpha (SIRPa,), that is expressed on the surface of macrophages and other myeloid immune cells.

The invention belongs to the technical field of biological medicine, and particularly relates to low-molecular-weight stemona polysaccharide (STP-3-2) as well as a preparation method and application thereof, and the weight-average molecular weight (Mw) of the low-molecular-weight stemona polysaccharide (STP-3-2) is between 15 kDa and 5 kDa. The preparation method comprises the following steps: taking dry tuberous roots of stemona tuberosa, extracting to obtain non-starch total polysaccharide of stemona tuberosa, and separating and purifying to obtain the low-molecular-weight stemona tuberosa polysaccharide. The polysaccharide can obviously activate macrophages, enhance the phagocytic function of the macrophages, promote secretion of nitric oxide (NO), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) and up-regulate expression of inducible nitric oxide synthase (iNOS), IL-6 and TNF-alpha mRNA, shows obvious immunological enhancement activity, does not have obvious toxic or side effects, and can be used for preparing the immunopotentiator. The polypeptide can be used for preparing medicines or functional foods for treating and / or preventing diseases such as immunosuppression and the like, and has a wide application prospect.

The invention relates to the technical field of biological medicines, in particular to a novel application of a BTK PROTAC compound NX-5948, and in particular relates to a novel application of a BTK PROTAC compound NX-5948 as a target chimera for degrading a Bruton's tyrosine kinase protein in a medicine for treating a secondary hemophagocytic syndrome (HLH). The BTK PROTAC compound NX-5948 in the invention inhibits activation of a BTK / NF-kappa B axis signal channel of macrophages in a targeted manner, on one hand, reduces the number of activated macrophages by inhibiting proliferation and survival of the macrophages, and on the other hand, induces polarization of the macrophages from pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages by virtue of an immunoregulation effect on the macrophages, so that the anti-inflammatory effect of the BTK PROTAC compound NX-5948 is improved, and the anti-inflammatory effect of the BTK PROTAC compound NX-5948 is improved. Therefore, the new application has the effects that the abnormal activation of macrophages can be inhibited, and clinical symptoms or laboratory indexes existing in patients with the secondary hemophagocytic syndrome can be improved.

The invention discloses sea cucumber glycoprotein MYP with immunocompetence and application of the sea cucumber glycoprotein MYP, and belongs to the technical field of marine biological activity. The immunocompetence protein MYP derived from the sea cucumber water extract is obtained, the MYP is obtained from the sea cucumber water extract through anion exchange chromatographic column purification, the immunomodulatory activity of the obtained protein is researched, and the result shows that the obtained sea cucumber glycoprotein can activate RAW264.7 macrophages to be converted from an M0 type to an M1 type, the phagocytic ability of the macrophages is improved, and the immunocompetence of the macrophages is improved. And the secretion of cell factors such as NO, ROS, IL-6, IL-1beta, TNF-alpha and the like can be effectively promoted. Meanwhile, the simulated digestion product of the MYP can also effectively promote the secretion of NO, ROS and cell factors of cells. And practical verification shows that the active protein MYP and the digestion product thereof have good immunomodulatory activity, and can provide technical basis and data support for subsequent industrial development.

The invention discloses a composite peptide premix feed capable of improving immunity of livestock and poultry aquatic products and a preparation method thereof, and relates to the technical field of feeds. In order to reduce the use amount of antibiotics in the livestock breeding process, a composite peptide component is added into the premix feed, and the use amount of the antibiotics is reduced by adding bovine lactoferrin peptide in the premix feed. Macrophages and natural killer cells are activated, immune globulin secretion is promoted, and the mucosal immune barrier function is enhanced, so that the autoimmunity of livestock is improved, and the disease resistance of the livestock is improved; and in order to avoid the defect that the feed is easy to mildew to generate mildew toxins, mildew-proof modified attapulgite clay is also prepared and added, so that the mildew speed after the premixed feed and the feed are mixed and watered is effectively slowed down, and the diarrhea rate of livestock is reduced.